Posted 01 November, 2021
Entrada Therapeutics, Inc. IPO completed
IPO completed detected for ticker Nasdaq:TRDA in a 424B4 filed on 01 November, 2021.
This is an initial public offering of shares of common stock of Entrada Therapeutics, Inc.
Don't know how to trade IPO completion? Read Initial Public Offerings.
Overview of Entrada Therapeutics, Inc.
Health Care/Life Sciences • Biotechnology
Entrada Therapeutics, Inc. operates as a biotechnology company. It focuses on delivery of biomolecules into the cell to treat devastating diseases. The firm offers intracellular enzyme replacement therapy and protein-protein interaction inhibitors programs. The company focuses on creating and expanding pipeline of oligonucleotide, antibody, enzyme, protein and peptide programs to target and engage underlying drivers of diseases. Entrada Therapeutics was founded by Dehua Pei in September 22, 2016 and is headquartered in Boston, MA.Market Cap
$413M
View Company Details
$413M
Interested in special situations?
Join Tickerverse
- customize event filters
- create watchlists, bookmarks
- get email notifications for the latest special situations
- browse and analyze public companies, executives and SEC filings
Tickerverse is a great way to find investment opportunities in corporate actions.
By signing up you agree to our Terms of Service and Privacy Policy.